Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease

An Institutional Experience and Review

Shazia Mirza, Umar Yazdani, Richard Dewey, Neepa Patel, Richard B. Dewey, Svjetlana Miocinovic, Shilpa Chitnis

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN) are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor, which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites, highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary team, tailored towards each patient's profile and their expectations, by drawing upon scientific evidence coupled with experience. Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute's DBS paradigm to ensure that patients receive the optimal therapy.

Original languageEnglish (US)
Article number3410820
JournalParkinson's Disease
Volume2017
DOIs
StatePublished - Jun 19 2017

Fingerprint

Subthalamic Nucleus
Globus Pallidus
Deep Brain Stimulation
Parkinson Disease
Knowledge Bases
Therapeutics
Quality of Life
Research

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease : An Institutional Experience and Review. / Mirza, Shazia; Yazdani, Umar; Dewey, Richard; Patel, Neepa; Dewey, Richard B.; Miocinovic, Svjetlana; Chitnis, Shilpa.

In: Parkinson's Disease, Vol. 2017, 3410820, 19.06.2017.

Research output: Contribution to journalReview article

@article{916e705dccf944cb8cd641459afcc3a4,
title = "Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review",
abstract = "Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN) are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor, which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites, highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary team, tailored towards each patient's profile and their expectations, by drawing upon scientific evidence coupled with experience. Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute's DBS paradigm to ensure that patients receive the optimal therapy.",
author = "Shazia Mirza and Umar Yazdani and Richard Dewey and Neepa Patel and Dewey, {Richard B.} and Svjetlana Miocinovic and Shilpa Chitnis",
year = "2017",
month = "6",
day = "19",
doi = "10.1155/2017/3410820",
language = "English (US)",
volume = "2017",
journal = "Parkinson's Disease",
issn = "2090-8083",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease

T2 - An Institutional Experience and Review

AU - Mirza, Shazia

AU - Yazdani, Umar

AU - Dewey, Richard

AU - Patel, Neepa

AU - Dewey, Richard B.

AU - Miocinovic, Svjetlana

AU - Chitnis, Shilpa

PY - 2017/6/19

Y1 - 2017/6/19

N2 - Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN) are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor, which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites, highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary team, tailored towards each patient's profile and their expectations, by drawing upon scientific evidence coupled with experience. Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute's DBS paradigm to ensure that patients receive the optimal therapy.

AB - Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN) are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor, which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites, highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary team, tailored towards each patient's profile and their expectations, by drawing upon scientific evidence coupled with experience. Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute's DBS paradigm to ensure that patients receive the optimal therapy.

UR - http://www.scopus.com/inward/record.url?scp=85021905791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021905791&partnerID=8YFLogxK

U2 - 10.1155/2017/3410820

DO - 10.1155/2017/3410820

M3 - Review article

VL - 2017

JO - Parkinson's Disease

JF - Parkinson's Disease

SN - 2090-8083

M1 - 3410820

ER -